Ramesh Arjunji

Ramesh Arjunji, PhD |  EVP, Value & Access

As EVP, Value and Access, Ramesh Arjunji, PhD brings a wealth of industry and academic experience including commercial, R&D, medical affairs and business development, from various biopharma leadership positions spanning neurology, oncology, immunology, metabolic, ophthalmology and medical devices.

Prior to joining Nanoscope, Dr. Arjunji served as Senior Vice President, Global Value and Access at Krystal Biotech and before that was Vice President and Head, Evidence Synthesis at SSI Strategy where he advised clients on evidence generation strategies. Earlier, Dr. Arjunji was VP, Value & Access at Avrobio, leading the development and execution of evidence generation strategies for lysosomal storage disorders gene therapy products. At AveXis/Novartis Gene Therapies, Dr. Arjunji led strategy and execution of global HTA engagement for Zolgensma, a gene therapy for Spinal Muscular Atrophy. Dr. Arjunji has also held leadership positions at GSK, Alcon, BMS, Biogen, Pfizer, Endo Pharmaceuticals, and Centocor/J&J.

On March 5, 2025   /    
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.